55 related articles for article (PubMed ID: 38701316)
1. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A; Smith DD; Cacciamani GE; Cole S; Shakir A; Sadeghi S; Vogelzang NJ; Quinn D; Gill PS; Gill IS
Clin Genitourin Cancer; 2020 Oct; 18(5):351-360.e3. PubMed ID: 32146152
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Liao PF; Wang PY; Peng TR
Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
7. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
8. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
9. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
[TBL] [Abstract][Full Text] [Related]
10. Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
Mani C; Acharya G; Saamarthy K; Ochola D; Mereddy S; Pruitt K; Manne U; Palle K
Breast Cancer Res; 2023 Apr; 25(1):44. PubMed ID: 37081516
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis.
Zeng S; Liu D; Yu Y; Zou L; Jin X; Liu B; Liu L
Front Pharmacol; 2023; 14():1111061. PubMed ID: 36992842
[No Abstract] [Full Text] [Related]
12. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
14. Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.
Dumitru A; Dobrica EC; Croitoru A; Cretoiu SM; Gaspar BS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292922
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
